Evoke Pharma 2025 Q3 Earnings 52.1% EPS Improvement Amid Revenue Surge

Evoke Pharma (EVOK) reported fiscal 2025 Q3 earnings on November 13, 2025, with revenue surging 61.4% year-over-year to $4.28 million, exceeding expectations. The company narrowed its net loss by 11.9% to $-1.16 million and improved GAAP EPS to -$0.45 from -$0.94. Guidance for the QOL Medical acquisition, expected to close in Q4 2025, underscores strategic optimism despite ongoing financial challenges.

Revenue

Third-quarter revenue surged to $4.28 million, driven entirely by net product sales, reflecting a 61.4% year-over-year increase from $2.65 million. The absence of distinct business segments beyond product sales highlights a focused revenue stream, with the full amount attributed to commercial performance of its gastrointestinal treatment portfolio.

Earnings/Net Income

Evoke Pharma reduced its net loss to $-1.16 million in Q3 2025, a 11.9% improvement from $-1.31 million in the prior-year period. GAAP EPS narrowed to -$0.45 from -$0.94, representing a 52.1% reduction in per-share losses. While the company has posted losses for five consecutive years in the quarter, the earnings contraction signals progress in cost management and operational efficiency.

Price Action

The stock demonstrated robust post-earnings performance, surging 126.48% month-to-date as of November 13, 2025. This outperformed its modest 0.56% weekly gain and 0.09% daily increase, suggesting investor confidence in the QOL Medical acquisition and GIMOTI’s extended patent life. The pronounced MTD rally aligns with the market’s positive reception to the proposed strategic transaction and commercial progress.

CEO Commentary

Matt D’Onofrio, CEO of Evoke Pharma, emphasized the QOL Medical acquisition as a pivotal milestone, citing Q3 net product sales of $4.3 million—a 61% year-over-year increase. He highlighted GIMOTI’s patent extension to 2038 and expanded pharmacy access as catalysts for value creation. The CEO framed the acquisition as an opportunity to accelerate growth under new leadership while maintaining operational focus, underscoring optimism for long-term shareholder returns.

Guidance

The company anticipates closing the QOL Medical acquisition in Q4 2025, pending shareholder approval and tender offer conditions. Evoke Pharma projects current cash balances of $11.6 million, combined with product revenues, to fund operations through Q4 2026. Management reiterated confidence in GIMOTI’s exclusivity through 2038 and the strategic benefits of the acquisition, aligning guidance with its long-term value proposition.

Additional News

Evoke Pharma’s acquisition by QOL Medical emerged as a focal point, with CEO Matt D’Onofrio labeling the deal a “strategic milestone.” The proposed transaction, centered on GIMOTI’s gastrointestinal treatment portfolio, has been positioned as a catalyst for growth. While no executive changes were announced, the acquisition highlights the company’s shift toward strategic partnerships to enhance commercial reach. No dividend or buyback initiatives were disclosed within the 21-day period preceding the earnings report.